Proportions of patients meeting definitions for progressive disease or improvement should be included in clinical trials for systemic sclerosis interstitial lung disease
Related Posts
Thorp M, Balakasi K, van Oosterhout JJ, Ramesh M, Robson I, Choko A, Shoptaw S, Hoffman R, Cornell M, Dovel K. High-Risk Mobility and Interruption[...]
Heerspink HJL, Neuen BL, Agarwal R, Cherney DZI, Lam CSP, Tuttle KR, Wanner C, Sarafidis P, Chertow GM, Friede T, Barratt J, Floege J, Chew-Wong[...]
Song J, Daniel M, Ardehali A. Not Yet a Nail in the Coffin for Ex Vivo Heart Perfusion. Ann Thorac Surg. 2026 Nov 15:S0003-4975(26)01175-6. doi:[...]